Polyhexamethylene biguanide for treatmemt of external genital warts: A prospective, double-blind, randomized study

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 6, 2005, Pages 369-372

  Marelli, G ^a   Papaleo, E ^a   Origoni, M ^a   Caputo, L ^a   Ferrari, A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Genital warts; Papillomavirus infection; Polyhexamethylene biguanide

Indexed keywords

PLACEBO; POLY(HEXAMETHYLENEBIGUANIDE); BIGUANIDE DERIVATIVE; DISINFECTANT AGENT;

ADULT; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE EXCORIATION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EROSION; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SKIN MANIFESTATION; SYSTEMIC DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; INTRADERMAL DRUG ADMINISTRATION; OINTMENT; PROSPECTIVE STUDY; PRURITUS; RECURRENT DISEASE; TIME; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ADULT; BIGUANIDES; CONDYLOMATA ACUMINATA; DISINFECTANTS; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; HUMANS; MALE; OINTMENTS; PROSPECTIVE STUDIES; PRURITUS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 31844443736     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Heaton CL. Clinical manifestations and modern management of condylomata acuminata: a dermatologic perspective. Am J Obstet Gynecol 1995; 172: 1344-1350.
2. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1983; 10: 122-163.
3. Spradbrow PB. Immune response to papillomavirus infection. In: K. Syrjänen, L. Gissmann, and L.G. Koss (ed.), Papillomaviruses and human disease. Springer-Verlag, Berlin, Germany, 1987, pp. 334-370.
4. Jablonska S, Majewski S. Immunology of genital papillomavirus infections. In: G. Gross, S. Jablonska, H. Pfister, H.E. Stegner (ed.), Genital papillomavirus infection. Springer-Verlag, Berlin (Germany), 1990, pp. 263-281.
5. Stone KM. Human papillomavirus infection and genital warts: update on epidemiology and treatment. Clin Infect Dis 1995; 20(Suppl. 1): S91-S97.
6. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986; 315: 1059-1064.
7. Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA 1988; 259: 533-538.
8. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferons administered intralesionally: a double-blind, placebo-controlled trial. Ann Intern Med 1988; 108: 675-679.
9. Stray-Pedersen B, Bergan T, Hafstad A, Normann E, Grogaard J, Vangdal M. Vaginal disinfection with chlorhexidine during childbirth. Int J Antimicrob Agents 1999; 12: 245-251
10. Beutner KR, Conant MA, Friedman-Kien AE, et al. Patient-applied podofilox for treatment of genital warts. Lancet 1989; 1: 831-834.
11. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991; 77: 735-739.
12. Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990; 88: 465-469.
13. Vance JC, Bart BJ, Hansen RC et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986; 122: 272-277.
14. Shubair M, Stanek R, White S, Larsen B. Effects of chlorhexidine gluconate douche on normal vaginal flora. Gynecol Obstet Invest 1992; 34: 229-233.
15. Sidky YA, Bryan GT, Weeks CE, Hatcher JM, Borden EC. Effects of treatment with an oral interferon inducer, imidazoquinolinamine (R-837), on the growth of mouse bladder carcinoma FCB, abstr. II6-12. J Interferon Res 1990; 10(Suppl. 1): S123.
16. Miller RL, Imbertson LM, Reiter MJ, Pecore SE, Gerster JF. Interferon induction by antiviral S-26308 in guinea pigs, abstr. 385, p. 168. In Program and abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C., 1986.
17. McKenzie RC, Sauder DN. Keratinocyte cytokines and growth factors: functions in skin immunity and homeostasis. Dermatol Clin 1990; 8: 649-661.
18. Harrison CJ, Jenski L, Miller RL, Bernstein DI. Treatment of genital HSV2 with R-837. Antivir Res 1988; 9: 125.
19. Bernstein DI, Miller RL, Harrison CJ. Adjuvant effects of polyhexamethylene biguanide on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis 1993; 167: 731-735.
20. Bernstein DI, Harrison CJ. Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections. Antimicrob Agents Chemother 1989; 33: 1511-1515.
21. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989; 20: 617-629.